Atlas-Backed Firm Will Seek Pan-Ataxia Therapy With Biogen’s Assistance
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.